Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
NCT ID: NCT06848348
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
200 participants
INTERVENTIONAL
2025-02-21
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo
Placebo
Placebo for Subcutaneous Injection
Halneuron
Halneuron
Halneuron
Halneuron for Subcutaneous Injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Halneuron
Halneuron for Subcutaneous Injection
Placebo
Placebo for Subcutaneous Injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Neuropathic pain has been present and is attributed to platinum and/or taxane chemotherapy.
* Patient has received a cancer chemotherapy regimen that included taxanes and/or platinum and has no active or discernible disease progression.
Exclusion Criteria
* Patients who have received HAL at any time prior to screening.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dogwood Therapeutics Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Recruiting Site
Sheffield, Alabama, United States
Central Recruiting Site
Glendale, Arizona, United States
Central Recruiting Site
Fair Oaks, California, United States
Central Recruiting Site
Fountain Valley, California, United States
Central Recruiting Site
Los Angeles, California, United States
Central Recruiting Site
Santa Rosa, California, United States
Central Recruiting Site
Wheat Ridge, Colorado, United States
Central Recruiting Site
Jacksonville, Florida, United States
Central Recruiting Site
Jacksonville, Florida, United States
Central Recruiting Site
Lakeland, Florida, United States
Central Recruiting Site
Orlando, Florida, United States
Central Recruiting Site
Port Charlotte, Florida, United States
Central Recruiting Site
Tampa, Florida, United States
Central Recruiting Site
Atlanta, Georgia, United States
Central Recruiting Site
Gurnee, Illinois, United States
Central Recruiting Site
Farmington, Michigan, United States
Central Recruiting Site
Fenton, Missouri, United States
Central Recruiting Site
Kansas City, Missouri, United States
Central Recruiting Site
Las Vegas, Nevada, United States
Central Recruiting Site
Garden City, New York, United States
Central Recruiting Site
Williamsville, New York, United States
Central Recruiting Site
Winston-Salem, North Carolina, United States
Central Recruiting Site
Salt Lake City, Utah, United States
Central Recruiting Site
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HAL-CINP-203
Identifier Type: -
Identifier Source: org_study_id